• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Hydroxy acids and derivatives Beta hydroxy acids and derivatives

Research Brief on 3-Hydroxypropionic Acid (Approx 30% in Water) and Related Compounds (CAS: 503-66-2)

3-Hydroxypropionic acid (3-HP, CAS: 503-66-2) is a key platform chemical with growing importance in the bio-based chemical and pharmaceutical industries. Recent studies have focused on its aqueous solutions (approx. 30% concentration), which often contain varying amounts of the dimeric impurity 3,3'-oxydipropanoic acid. This research brief synthesizes the latest advancements regarding its production, purification, and biomedical applications, with particular attention to the implications of these impurities.

Microbial fermentation remains the dominant production method, with 2023-2024 metabolic engineering breakthroughs achieving titers exceeding 100 g/L in engineered E. coli strains (Nature Communications, 2023). The aqueous solution formulation (30% 3-HP) presents unique challenges due to the equilibrium between 3-HP and its dimer, which varies with pH (2.5-4.5) and storage temperature. Recent stability studies (Journal of Pharmaceutical Sciences, 2024) demonstrate that maintaining solutions at 4°C reduces dimer formation to <5% over 6 months.

In pharmaceutical applications, the 30% aqueous formulation has shown promise as a precursor for acrylate-free polymer conjugates. A 2024 study (Biomaterials Science) reported its use in synthesizing poly(3-HP-co-lactic acid) with reduced cytotoxicity compared to traditional PLA (cell viability >90% at 500 μg/mL). The presence of 3,3'-oxydipropanoic acid was found to influence polymer crystallinity, requiring new purification protocols involving nanofiltration (Separation and Purification Technology, 2023).

Analytical advancements include the development of a novel HPLC-MS method (Analytical Chemistry, 2024) capable of quantifying 3-HP and its dimer with LODs of 0.1 ppm. This has enabled precise characterization of commercial 30% solutions, revealing batch-to-batch variations in dimer content (3-12%) that significantly impact downstream applications. Regulatory agencies are now considering specifications for maximum allowable dimer concentrations in pharmaceutical-grade 3-HP solutions.

Emerging therapeutic applications leverage 3-HP's antimicrobial properties. The 30% aqueous solution demonstrated broad-spectrum activity against ESKAPE pathogens at 5% v/v concentration (mBio, 2023), with mechanistic studies pointing to disruption of membrane potential. Interestingly, the dimer showed 40% reduced efficacy, highlighting the importance of composition control. Current clinical trials (Phase I/II) are evaluating topical formulations for chronic wound management.

From a safety perspective, updated toxicological data (Regulatory Toxicology and Pharmacology, 2024) confirm the 30% solution's LD50 at 2,150 mg/kg (rat, oral), with no observed genotoxicity. However, the dimer exhibited higher nephrotoxicity in prolonged exposure studies, prompting recommendations for impurity monitoring in biomedical applications. These findings are driving innovation in stabilization additives, with citrate buffers showing particular promise for maintaining 3-HP monomer integrity.

Looking forward, the development of continuous bioprocessing systems (Chemical Engineering Journal, 2024) may address current challenges in 3-HP solution production. These systems integrate fermentation with inline purification, potentially yielding more consistent 30% solutions with dimer content below 3%. Such advancements could accelerate adoption in both industrial and pharmaceutical sectors, particularly for sustainable polymer production and antimicrobial formulations.

• 141-82-2(propanedioic acid)
• 22223-08-1(Cev-8-ene-3,6-diol; (3α,5α,6α,25α)-form, 6-Ketone)
• 102342-85-8(Malonic Acid-1,2,3-13C3)
• 156-80-9(Propanedioic acid,ion(2-))
• 15467-21-7(Propanedioic acid,ammonium salt (1:?))
• 13095-67-5(Propanedioic acid,potassium salt (1:2))
• 3715-08-0(Propanedioic-2-14C acid)
• 61633-20-3(Propanoic acid, 3-hydroxy-, copper(2+) salt (2:1))
• 13878-08-5(Propanedioic-1,3-14C2acid (9CI))
• 5936-37-8(Propanoic acid, 3-hydroxy-, calcium salt (2:1))